All In Biotech

Drug Trial Radar · NCT06903611

Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye

CAMOMILE-2: Phase III Randomized, Double-Masked, Safety and Efficacy Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Vehicle Control for the Treatment of Moderate to Severe Dry Eye

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 475 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

475

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Nov 30, 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Cambium Bio LimitedIndustry
Sponsor type
Industry
First posted
Mar 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for one year.

Conditions

  • Dry Eye Disease
  • Dry Eye
  • Dry Eyes Chronic
  • Dry Eye Syndromes

Interventions

  • CAM-101Drug

    fibrinogen depleted human platelet lysate

  • Vehicle ControlOther

    Plasmalyte-A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Corneal FluoresceinTime frame: 9 weeks
  2. Eye DiscomfortTime frame: 9 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.